BR0214859A - Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um mamìfero, incluindo um humano, sofrendo de ou suscetìvel a um distúrbio do sistema nervoso central - Google Patents
Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um mamìfero, incluindo um humano, sofrendo de ou suscetìvel a um distúrbio do sistema nervoso centralInfo
- Publication number
- BR0214859A BR0214859A BR0214859-5A BR0214859A BR0214859A BR 0214859 A BR0214859 A BR 0214859A BR 0214859 A BR0214859 A BR 0214859A BR 0214859 A BR0214859 A BR 0214859A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- susceptible
- human
- treatment
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000015114 central nervous system disease Diseases 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0130339.5A GB0130339D0 (en) | 2001-12-19 | 2001-12-19 | Isochroman compounds |
| PCT/US2002/036148 WO2003053948A1 (en) | 2001-12-19 | 2002-12-06 | Isochroman compounds for treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0214859A true BR0214859A (pt) | 2004-11-03 |
Family
ID=9927920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0214859-5A BR0214859A (pt) | 2001-12-19 | 2002-12-06 | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um mamìfero, incluindo um humano, sofrendo de ou suscetìvel a um distúrbio do sistema nervoso central |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1458703B1 (enExample) |
| JP (1) | JP2005516952A (enExample) |
| CN (1) | CN1312148C (enExample) |
| AR (1) | AR038662A1 (enExample) |
| AT (1) | ATE355283T1 (enExample) |
| AU (1) | AU2002359378B8 (enExample) |
| BR (1) | BR0214859A (enExample) |
| CA (1) | CA2469278A1 (enExample) |
| CY (1) | CY1106552T1 (enExample) |
| DE (1) | DE60218529T2 (enExample) |
| DK (1) | DK1458703T3 (enExample) |
| ES (1) | ES2280606T3 (enExample) |
| GB (1) | GB0130339D0 (enExample) |
| MX (1) | MXPA04006085A (enExample) |
| PE (1) | PE20030728A1 (enExample) |
| PT (1) | PT1458703E (enExample) |
| SI (1) | SI1458703T1 (enExample) |
| SV (1) | SV2004001441A (enExample) |
| TW (1) | TW200301116A (enExample) |
| WO (1) | WO2003053948A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| NL2000351C2 (nl) | 2005-12-22 | 2007-09-11 | Pfizer Prod Inc | Estrogeen-modulatoren. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4247553A (en) * | 1977-10-31 | 1981-01-27 | The Upjohn Company | Methods of treating psychosis |
| ES2133714T3 (es) * | 1993-12-28 | 1999-09-16 | Upjohn Co | Compuestos heterociclicos para el tratamiento de trastornos del snc y cardiovasculares. |
| MX9710260A (es) * | 1995-06-30 | 1998-03-29 | Upjohn Co | Isocromanos 1, 6-disustituidos para el tratamiento de migrañas. |
| GB2370270A (en) * | 2000-12-20 | 2002-06-26 | Lilly Co Eli | Pharmaceutical compounds |
-
2001
- 2001-12-19 GB GBGB0130339.5A patent/GB0130339D0/en not_active Ceased
-
2002
- 2002-11-18 TW TW091133608A patent/TW200301116A/zh unknown
- 2002-12-06 WO PCT/US2002/036148 patent/WO2003053948A1/en not_active Ceased
- 2002-12-06 DK DK02793911T patent/DK1458703T3/da active
- 2002-12-06 DE DE60218529T patent/DE60218529T2/de not_active Expired - Lifetime
- 2002-12-06 EP EP02793911A patent/EP1458703B1/en not_active Expired - Lifetime
- 2002-12-06 SI SI200230528T patent/SI1458703T1/sl unknown
- 2002-12-06 PT PT02793911T patent/PT1458703E/pt unknown
- 2002-12-06 JP JP2003554664A patent/JP2005516952A/ja not_active Ceased
- 2002-12-06 CA CA002469278A patent/CA2469278A1/en not_active Abandoned
- 2002-12-06 MX MXPA04006085A patent/MXPA04006085A/es active IP Right Grant
- 2002-12-06 ES ES02793911T patent/ES2280606T3/es not_active Expired - Lifetime
- 2002-12-06 BR BR0214859-5A patent/BR0214859A/pt not_active IP Right Cessation
- 2002-12-06 CN CNB028281209A patent/CN1312148C/zh not_active Expired - Fee Related
- 2002-12-06 AU AU2002359378A patent/AU2002359378B8/en not_active Ceased
- 2002-12-06 AT AT02793911T patent/ATE355283T1/de not_active IP Right Cessation
- 2002-12-13 PE PE2002001229A patent/PE20030728A1/es not_active Application Discontinuation
- 2002-12-18 AR ARP020104961A patent/AR038662A1/es unknown
- 2002-12-19 SV SV2002001441A patent/SV2004001441A/es not_active Application Discontinuation
-
2007
- 2007-04-26 CY CY20071100573T patent/CY1106552T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1458703A1 (en) | 2004-09-22 |
| DE60218529T2 (de) | 2007-11-22 |
| JP2005516952A (ja) | 2005-06-09 |
| DE60218529D1 (de) | 2007-04-12 |
| CN1312148C (zh) | 2007-04-25 |
| AU2002359378B2 (en) | 2008-08-21 |
| MXPA04006085A (es) | 2004-09-27 |
| AU2002359378B8 (en) | 2008-09-11 |
| ES2280606T3 (es) | 2007-09-16 |
| SI1458703T1 (sl) | 2007-08-31 |
| AU2002359378A1 (en) | 2003-07-09 |
| CA2469278A1 (en) | 2003-07-03 |
| EP1458703B1 (en) | 2007-02-28 |
| SV2004001441A (es) | 2004-05-07 |
| WO2003053948A1 (en) | 2003-07-03 |
| AR038662A1 (es) | 2005-01-26 |
| GB0130339D0 (en) | 2002-02-06 |
| PT1458703E (pt) | 2007-05-31 |
| CN1620447A (zh) | 2005-05-25 |
| CY1106552T1 (el) | 2012-01-25 |
| ATE355283T1 (de) | 2006-03-15 |
| PE20030728A1 (es) | 2003-08-29 |
| TW200301116A (en) | 2003-07-01 |
| DK1458703T3 (da) | 2007-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
| BR9911488A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| BRPI0215312B8 (pt) | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
| BR9914696A (pt) | Composto, processo para tratamento de distúrbio mediado por ciclo-oxigenase-2 em um indivìduo, e, composição farmacêutica | |
| BR0213242A (pt) | Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto | |
| BR9714082A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto. | |
| EA200000759A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| BR0208891A (pt) | Derivados de dihidro-benzo[b]-[1,4]diazepin-2-ona como antagonistas de mglur2 ii | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
| BR9914638A (pt) | Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo | |
| BR0203644A (pt) | Derivados heteroarìlicos dissubstituìdos com ácido como inibidores de metaloproteinase de matriz | |
| BR9912406A (pt) | Compostos de anilida substituida e métodos | |
| BR0213540A (pt) | Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos | |
| BRPI0411484A (pt) | composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica | |
| BR0310077A (pt) | Novos compostos e sua utilização | |
| BRPI0410316A (pt) | composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores | |
| MA26608A1 (fr) | Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque. | |
| ATE444073T1 (de) | Oxalate-abbauende mikroorganismen oder oxalate- abbauende enzyme zur verhütung der oxalate- verwandten krankheiten | |
| BRPI0208468B8 (pt) | camsilato de amlodipina e processo para sua preparação | |
| BRPI0409739A (pt) | composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio | |
| BR0215395A (pt) | Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue | |
| BR0211635A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um indivìduo sofrendo de ou propenso à doença de alzheimer | |
| BR0214859A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um mamìfero, incluindo um humano, sofrendo de ou suscetìvel a um distúrbio do sistema nervoso central |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |